WO2021229016A1 - Calprotectin assay - Google Patents

Calprotectin assay Download PDF

Info

Publication number
WO2021229016A1
WO2021229016A1 PCT/EP2021/062753 EP2021062753W WO2021229016A1 WO 2021229016 A1 WO2021229016 A1 WO 2021229016A1 EP 2021062753 W EP2021062753 W EP 2021062753W WO 2021229016 A1 WO2021229016 A1 WO 2021229016A1
Authority
WO
WIPO (PCT)
Prior art keywords
terminus
hne
monoclonal antibody
disease
calprotectin
Prior art date
Application number
PCT/EP2021/062753
Other languages
English (en)
French (fr)
Inventor
Joachim Høg MORTENSEN
Dovile SINKEVICIUTE
Tina MANON-JENSEN
Morten Asser Karsdal
Anne-Christine BAY-JENSEN
Signe Holm NIELSEN
Annika Hummersgaard HANSEN
Jannie Marie Bülow SAND
Diana Julie LEEMING
Nicholas WILLUMSEN
Christina Jensen
Original Assignee
Nordic Bioscience A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2007087.6A external-priority patent/GB202007087D0/en
Priority claimed from GBGB2100902.2A external-priority patent/GB202100902D0/en
Application filed by Nordic Bioscience A/S filed Critical Nordic Bioscience A/S
Priority to US17/925,005 priority Critical patent/US20230184787A1/en
Priority to JP2022568548A priority patent/JP2023527702A/ja
Priority to EP21725522.3A priority patent/EP4150337A1/en
Priority to KR1020227042638A priority patent/KR20230009421A/ko
Priority to CN202180034810.7A priority patent/CN115836223A/zh
Publication of WO2021229016A1 publication Critical patent/WO2021229016A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/10—Competitive assay format
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
PCT/EP2021/062753 2020-05-13 2021-05-12 Calprotectin assay WO2021229016A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/925,005 US20230184787A1 (en) 2020-05-13 2021-05-12 Calprotectin Assay
JP2022568548A JP2023527702A (ja) 2020-05-13 2021-05-12 カルプロテクチンアッセイ
EP21725522.3A EP4150337A1 (en) 2020-05-13 2021-05-12 Calprotectin assay
KR1020227042638A KR20230009421A (ko) 2020-05-13 2021-05-12 칼프로텍틴 검정
CN202180034810.7A CN115836223A (zh) 2020-05-13 2021-05-12 钙防卫蛋白测定

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2007087.6A GB202007087D0 (en) 2020-05-13 2020-05-13 Calprotectin assay
GB2007087.6 2020-05-13
GBGB2100902.2A GB202100902D0 (en) 2021-01-22 2021-01-22 Calprotectin assay
GB2100902.2 2021-01-22

Publications (1)

Publication Number Publication Date
WO2021229016A1 true WO2021229016A1 (en) 2021-11-18

Family

ID=75914545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/062753 WO2021229016A1 (en) 2020-05-13 2021-05-12 Calprotectin assay

Country Status (6)

Country Link
US (1) US20230184787A1 (zh)
EP (1) EP4150337A1 (zh)
JP (1) JP2023527702A (zh)
KR (1) KR20230009421A (zh)
CN (1) CN115836223A (zh)
WO (1) WO2021229016A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891103A (zh) * 2022-06-11 2022-08-12 巴迪泰(青岛)生物科技有限公司 一种钙卫蛋白单克隆抗体及试剂盒
CN115684432A (zh) * 2023-01-04 2023-02-03 北京和合医学诊断技术股份有限公司 一种血液中钙卫蛋白含量的检测方法及检测试剂盒
WO2023209055A1 (en) * 2022-04-28 2023-11-02 Bühlmann Laboratories Ag Calprotectin binding peptides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430701A (zh) * 2023-12-20 2024-01-23 南京佰抗生物科技有限公司 抗人钙卫蛋白的单克隆抗体组合物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004057341A2 (en) * 2002-12-20 2004-07-08 Axis-Shield Asa Cvd assay
EP2081028A1 (fr) * 1999-07-15 2009-07-22 bioMérieux S.A. Utilisation d'un polypeptide pour détecter, prévenir ou traiter un état pathologique associé à une maladie dégénérative, neurologique autoimmune
WO2017079653A2 (en) * 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081028A1 (fr) * 1999-07-15 2009-07-22 bioMérieux S.A. Utilisation d'un polypeptide pour détecter, prévenir ou traiter un état pathologique associé à une maladie dégénérative, neurologique autoimmune
WO2004057341A2 (en) * 2002-12-20 2004-07-08 Axis-Shield Asa Cvd assay
WO2017079653A2 (en) * 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. UP000005640
ALFAKRY H.MALLE E.KOYANI CN. ET AL.: "Neutrophil proteolytic activation cascades: a possible mechanistic link between chronic periodontitis and coronary heart disease", INNATE IMMUN, vol. 22, no. 1, 2016, pages 85 - 99
CARLSEN K.MALHAM M.HANSEN LF. ET AL.: "Serum Calprotectin in Adolescents With Inflammatory Bowel Disease-A Pilot Investigation", J PEDIATR GASTROENTEROL NUTR, vol. 68, no. 5, 2019
CHANG M-H.CHOU J-W.CHEN S-M. ET AL.: "Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome", MOL MED REP, vol. 10, no. 1, 2014, pages 522 - 6
DORING G: "The Role of Neutrophil Elastase in Chronic Inflammation", AM J RESPIR CRIT CARE MED, vol. 150, no. 6, 1994, pages 114 - 7
FUKUNAGA S.KUWAKI K.MITSUYAMA K. ET AL.: "Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization", INT J MOL MED, vol. 2017, pages 107 - 18
GEBOES K: "Histopathology of Crohn ' s Disease and Ulcerative Colitis", INFLAMMATORY BOWEL DISEASE, vol. 18, 2003, pages 255 - 76
GIONCHETTI P.DIGNASS A.DANESE S. ET AL.: "3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations", J CROHN'S COLITIS, vol. 11, no. 2, 2017, pages 135 - 49
GOFFIN L.FAGAGNINI S.VICARI A. ET AL.: "Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis", INFLAMM BOWEL DIS, vol. 22, no. 9, 2016, pages 2041 - 57, XP055455514, DOI: 10.1097/MIB.0000000000000863
GOUNI-BERTHOLD I: "Neutrophil-elastase in chronic inflammatory bowel disease: A marker of disease activity?", HEPATOGASTROENTEROLOGY, vol. 46, no. 28, 1999, pages 2315 - 20, XP009193626
GRETEN FRGRIVENNIKOV SI: "Inflammation and Cancer: Triggers, Mechanisms, and Consequences", IMMUNITY, vol. 51, no. 1, 16 July 2019 (2019-07-16), pages 27 - 41, XP085736146, DOI: 10.1016/j.immuni.2019.06.025
HAMMER HB.0DEG°ARD S.FAGERHOL MK. ET AL.: "Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis", ANN RHEUM DIS, vol. 66, no. 8, 2007, pages 1093 - 7
HOSKIN TSCROWTHER JMCHEUNG J ET AL.: "Oxidative cross-linking of calprotectin occurs in vivo, altering its structure and susceptibility to proteolysis", REDOX BIOL, vol. 24, 2019, pages 101202
JASPER AEMCIVER WJSAPEY EWALTON GM: "Understanding the role of neutrophils in chronic inflammatory airway disease", F1000RES, vol. 8, 26 April 2019 (2019-04-26), pages F1000
JOACHIM HØG MORTENSEN ET AL: "Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease", PLOS ONE, vol. 12, no. 10, 13 October 2017 (2017-10-13), pages e0185855, XP055538751, DOI: 10.1371/journal.pone.0185855 *
KABAT, E. A.T. T. WUH. M. PERRYK. S. GOTTESMANC. FOELLER: "Sequences of Proteins of Immunological Interest", 1987, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 1
KALLA R.KENNEDY NA.VENTHAM NT. ET AL.: "Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases", AM J GASTROENTEROL, vol. 111, no. 12, 2016
KIROV S.SASSON A.ZHANG C. ET AL.: "Degradation of the extracellular matrix is part of the pathology of ulcerative colitis", MOL OMI, vol. 15, no. I, 2019, pages 67 - 76
KOPI TA.SHAHROKH S.MIRZAEI A. ET AL.: "The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: A review study", GASTROENTEROL HEPATOL FROM BED TO BENCH, vol. 12, no. 3, 2019, pages 183 - 9
KRISTENSEN JH.KARSDAL MA.SAND JM. ET AL.: "Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling", BMC PULM MED, vol. 15, no. 1, 2015, pages 53, XP021221151, DOI: 10.1186/s12890-015-0048-5
LABAERE D.SMISMANS A.VAN OLMEN A. ET AL.: "Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease", UNITED EUR GASTROENTEROL J, vol. 2, no. 1, 2014, pages 30 - 7, XP055261794, DOI: 10.1177/2050640613518201
LEVINE AP.SEGAL AW.: "What Is wrong with granulocytes in inflammatory bowel diseases", DIG DIS, vol. 31, 2013, pages 321 - 7
LINDHOLM M.MANON-JENSEN T.MADSEN GI. ET AL.: "Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis", DIG DIS SCI, 2019
LOBATON T.BESSISSOW T.DE HERTOGH G. ET AL.: "The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients", J CROHNS COLITIS, vol. 9, no. 10, 2015, pages 846 - 52
MAGRO F.GIONCHETTI P.ELIAKIM R. ET AL.: "Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer, Surveillance, Surgery, and Ileo-anal Pouch Disorders", J CROHN'S COLITIS, vol. 2017, pages 1 - 115
MALHAM M.CARLSEN K.RIIS L. ET AL.: "Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis", SCAND J GASTROENTEROL, vol. 54, no. 10, 2019, pages 1214 - 9
MARTINEZ FJCOLLARD HRPARDO ARAGHU GRICHELDI LSELMAN MSWIGRIS JJTANIGUCHI HWELLS AU: "Idiopathic pulmonary fibrosis", NAT REV DIS PRIMERS, vol. 3, 20 October 2017 (2017-10-20), pages 17074
MCCANN RK.SMITH K.GAYA DR.: "A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients", CLIN BIOCHEM, vol. 50, no. 9, 2017, pages 533 - 6, XP085073545, DOI: 10.1016/j.clinbiochem.2017.01.006
MEUWIS MA.VERNIER-MASSOUILLE G.GRIMAUD JC. ET AL.: "Serum calprotectin as a biomarker for Crohn's disease", J CROHN'S COLITIS, vol. 7, no. 12, 2013, pages e678 - 83, XP028773452, DOI: 10.1016/j.crohns.2013.06.008
MORTENSEN JH.GODSKESEN LE.JENSEN MD. ET AL.: "Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis", J CROHN'S COLITIS, vol. 2015, pages jjvl23
MORTENSEN JH.LINDHOLM M.LANGHOLM LL. ET AL.: "The intestinal tissue homeostasis - the role of extracellular matrix remodeling in inflammatory bowel disease", EXPERT REV GASTROENTEROL HEPATOL, vol. 00, no. 00, 2019, pages l-17
MORTENSEN JH.MANON-JENSEN T.JENSEN MD. ET AL.: "Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease", PLOS ONE, vol. 12, no. 10, 2017, pages 1 - 16, XP055538751, DOI: 10.1371/journal.pone.0185855
OBAYASHI YYAMADORI IFUJITA JYOSHINOUCHI TUEDA NTAKAHARA J: "The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis", CHEST, vol. 112, no. 5, 5 November 1997 (1997-11-05), pages 1338 - 43
ROSETH AG.FAGERHOL MK.AADLAND E. ET AL.: "Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study", SCAND J GASTROENTEROL, vol. 27, no. 9, 1992, pages 793 - 8, XP009110340, DOI: 10.3109/00365529209011186
SAND JMMARTINEZ GMIDJORD AKKARSDAL MALEEMING DJLANGE P: "Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease", CLIN BIOCHEM., vol. 49, no. 15, 7 September 2016 (2016-09-07), pages 1144 - 1151
SCHOEPFER AM.TRUMMLER M.SEEHOLZER P. ET AL.: "Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies", INFLAMM BOWEL DIS, vol. 14, no. I, 2008, pages 32 - 9, XP002753939, DOI: 10.1002/ibd.20275
STEPHAN JR.NOLAN EM.: "Calcium-induced tetramerization and zinc chelation shield human calprotectin from degradation by host and bacterial extracellular proteases", CHEM SCI, vol. 7, no. 3, 2016, pages 1962 - 75
TARDIF MR.CHAPETON-MONTES JA.POSVANDZIC A. ET AL.: "Secretion of S100A8, S100A9, and S100A12 by Neutrophils Involves Reactive Oxygen Species and Potassium Efflux", J IMMUNOL RES, vol. 2015, 2015
URBAN CF.ERMERT D.SCHMID M. ET AL., NEUTROPHIL EXTRACELLULAR TRAPS CONTAIN CALPROTECTIN , A CYTOSOLIC PROTEIN COMPLEX INVOLVED IN HOST DEFENSE AGAINST CANDIDA ALBICANS, vol. 5, no. 10, 2009
VAN HAAFTEN WT.MORTENSEN JH.KARSDAL MA. ET AL.: "Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease", ALIMENT PHARMACOL THER, August 2016 (2016-08-01)
WERA 0.LANCELLOTTI P.OURY C.: "The Dual Role of Neutrophils in Inflammatory Bowel Diseases", J CLIN MED, vol. 5, no. 12, 2016, pages 118

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023209055A1 (en) * 2022-04-28 2023-11-02 Bühlmann Laboratories Ag Calprotectin binding peptides
CN114891103A (zh) * 2022-06-11 2022-08-12 巴迪泰(青岛)生物科技有限公司 一种钙卫蛋白单克隆抗体及试剂盒
CN115684432A (zh) * 2023-01-04 2023-02-03 北京和合医学诊断技术股份有限公司 一种血液中钙卫蛋白含量的检测方法及检测试剂盒

Also Published As

Publication number Publication date
US20230184787A1 (en) 2023-06-15
EP4150337A1 (en) 2023-03-22
KR20230009421A (ko) 2023-01-17
CN115836223A (zh) 2023-03-21
JP2023527702A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
US20230184787A1 (en) Calprotectin Assay
Kristensen et al. Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders
CN108291917B (zh) 检测裂解的高分子量激肽原的免疫测定方法
ES2900363T3 (es) Ensayo de colágeno tipo VII alfa 1
EA034364B1 (ru) Иммуноанализ для обнаружения хромогранина а
JP6505749B2 (ja) 肺疾患および他の疾患用の生化学マーカー
TWI397687B (zh) 腎病變相關之生物標記的應用及其中所使用的套組
JP2023522052A (ja) 線維症のバイオマーカー
EP4070112B1 (en) A neo-epitope specific assay measuring protease mediated degradation of type iv collagen
US20230052142A1 (en) Tumstatin Assay
US20240011997A1 (en) Elastin Assay
US20230280350A1 (en) Collagen Type XVI Assay
US20230152323A1 (en) SPARC Assay
KR20230145319A (ko) 콜라겐 xviii 바이오마커 검출용 검정
KR20230154299A (ko) 콜라겐 xi 바이오마커 검출용 검정
WO2024056833A1 (en) Immunoassay for detecting a n-terminal peptide of a proteolytic cleavage product of cartilage intermediate layer protein-1
WO2023079130A1 (en) Collagen type xxii assay
WO2023148165A1 (en) Method for diagnosing collagen degradatation associated disease
US20200340994A1 (en) Tumstatin Assay
KR20230146014A (ko) 호산구성 식도염 검출을 위한 면역분석법
EP4356137A1 (en) Collagen type xx assay
US20190257837A1 (en) Nidogen-1 Fragments Assay
WO2023139154A1 (en) A method for detecting covid-19 in a patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21725522

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022568548

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227042638

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021725522

Country of ref document: EP

Effective date: 20221213